Navigation Links
Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules

BOCA RATON, Fla., March 26, 2013 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has entered into an agreement with Aptalis Pharmatech, Inc. to market Propranolol Hydrochloride Extended-Release Capsules, USP the generic version of Inderal® LA by Akrimax Pharmaceuticals, LLC, under Aptalis Pharmatech, Inc.'s Abbreviated New Drug Application (ANDA). The product was approved by the U.S. Food and Drug Administration (FDA) on July 15, 2011.  Under the terms of this agreement, Aptalis Pharmatech, Inc. will manufacture and supply the product to Breckenridge Pharmaceutical, Inc., who will have exclusive marketing and distribution rights in the U.S.  The companies have already begun shipping the product.

Propranolol Hydrochloride Extended-Release Capsules are indicated to treat hypertension, angina pectoris due to coronary atherosclerosis, migraine, and hypertrophic subaortic stenosis.

The current generic market is approximately $75 million USD, based on industry sales data.  The product is available in 4 strengths: 60mg, 80mg, 120mg and 160mg.

About Breckenridge Pharmaceutical, Inc.

Breckenridge is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products and Medical Foods in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 60 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, and Liquids, and Powders.

About Aptalis:

Aptalis Pharma™ is a privately held, leading specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. Aptalis has manufacturing and commercial operations in the United States, the European Union and Canada, and its products include ZENPEP®, CANASA®, CARAFATE®, PYLERA®, RECTIV®, VIOKACE™, ULTRESA, LACTEOL®, DELURSAN®, PANZYTRAT®, and SALOFALK®. Aptalis also formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, and taste-masking/orally disintegrating tablet (ODT) formulations. For more information, visit

SOURCE Breckenridge Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Breckenridge Announces Approval for Pioglitazone Hydrochloride tablets
2. TriReme Announces Signing of a Master Distribution Agreement in China
3. Genalyte Announces CE Mark For Maverick(TM) Detection System And Signs On First European Distributors
4. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
5. ECRI Institute Announces 2013 Health Devices Achievement Award -- Call for Entries
6. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
7. Research and Markets Announces The Release of Neuromodulation Market - Forecasts to 2017
8. SARcode Bioscience Announces Acquisition by Shire US Holdings Inc.
9. Creative Edge Nutrition, Inc. Announces the Entrance into the Medical Marijuana Sector
10. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
11. United Therapeutics Announces Receipt Of Second Complete Response Letter For Oral Treprostinil NDA
Post Your Comments:
(Date:11/25/2015)... N.Y. , Nov. 25, 2015  Henry Schein, ... and services to office-based dental, medical and animal health ... (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion , ... broadest array of open solutions designed to help any ... Click here for a schedule of experts ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Trovagene, ... molecular diagnostics, today announced that Chief Executive Officer Antonius ... at the 27 th Annual Piper Jaffray Healthcare ... Conference at the New York Palace Hotel in ... 2015 at 1:30 p.m. EST. Mr. Schuh will be ...
(Date:11/25/2015)... 2015 Endo International plc (NASDAQ: ENDP ) ... President and CEO, will discuss corporate updates at the 27 ... New York on Wednesday, December 2, 2015 at ... Investor Relations, and then the link to the event. Participants ... time to visit the site and download any streaming media ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of the common symptoms of ... and dry skin. But many people who find their cholesterol levels and weight are ... their thyroid, especially if they don’t have any of the other symptoms. , Thyroid ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion Bootie ... an early celebration of the early holiday shopping season. Starting Wednesday November 25th, ... $33.95 ea). Black Friday promotional pricing is in addition to any automatic discounts ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... to offer their patients the many benefits of the revolutionary BIOLASE WaterLase iPlus ... cutting and scraping tools traditionally used by a dentist in Gettysburg, PA ...
Breaking Medicine News(10 mins):